JP2013515015A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515015A5
JP2013515015A5 JP2012545030A JP2012545030A JP2013515015A5 JP 2013515015 A5 JP2013515015 A5 JP 2013515015A5 JP 2012545030 A JP2012545030 A JP 2012545030A JP 2012545030 A JP2012545030 A JP 2012545030A JP 2013515015 A5 JP2013515015 A5 JP 2013515015A5
Authority
JP
Japan
Prior art keywords
composition
polypeptide
immunogenic
pharmaceutically acceptable
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012545030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515015A (ja
JP5894083B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2010/001977 external-priority patent/WO2011075823A1/en
Publication of JP2013515015A publication Critical patent/JP2013515015A/ja
Publication of JP2013515015A5 publication Critical patent/JP2013515015A5/ja
Application granted granted Critical
Publication of JP5894083B2 publication Critical patent/JP5894083B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012545030A 2009-12-22 2010-12-20 免疫原性組成物 Expired - Fee Related JP5894083B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28923609P 2009-12-22 2009-12-22
US61/289,236 2009-12-22
US32566010P 2010-04-19 2010-04-19
US61/325,660 2010-04-19
PCT/CA2010/001977 WO2011075823A1 (en) 2009-12-22 2010-12-20 Immunogenic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015254259A Division JP2016104776A (ja) 2009-12-22 2015-12-25 免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2013515015A JP2013515015A (ja) 2013-05-02
JP2013515015A5 true JP2013515015A5 (cg-RX-API-DMAC7.html) 2015-01-29
JP5894083B2 JP5894083B2 (ja) 2016-03-23

Family

ID=44194860

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012545030A Expired - Fee Related JP5894083B2 (ja) 2009-12-22 2010-12-20 免疫原性組成物
JP2015254259A Pending JP2016104776A (ja) 2009-12-22 2015-12-25 免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015254259A Pending JP2016104776A (ja) 2009-12-22 2015-12-25 免疫原性組成物

Country Status (12)

Country Link
US (1) US20130183350A1 (cg-RX-API-DMAC7.html)
EP (1) EP2515938A4 (cg-RX-API-DMAC7.html)
JP (2) JP5894083B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120107121A (cg-RX-API-DMAC7.html)
CN (1) CN102802664B (cg-RX-API-DMAC7.html)
AR (1) AR079712A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010335970B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012018343A2 (cg-RX-API-DMAC7.html)
CA (1) CA2783955A1 (cg-RX-API-DMAC7.html)
IL (2) IL220576B (cg-RX-API-DMAC7.html)
WO (1) WO2011075823A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201204628B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939105B (zh) 2009-12-22 2016-11-16 赛诺菲巴斯德有限公司 免疫原性组合物和相关的方法
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドSanofi Pasteur Limited 肺炎球菌に対する免疫用組成物
EA201391456A1 (ru) 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
JP6236086B2 (ja) * 2012-10-17 2017-11-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 1種以上の肺炎球菌莢膜糖類コンジュゲートとインフルエンザ菌由来のタンパク質Eおよび/またはPilAを含むタンパク質成分とを含む免疫原性組成物
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
AU2015228542A1 (en) * 2014-03-10 2016-09-22 Sanofi Pasteur Limited Immunogenic compositions
KR101688960B1 (ko) * 2014-06-11 2016-12-23 전남대학교산학협력단 스쿠티카충 백신 조성물
SG11201706081SA (en) * 2015-01-27 2017-08-30 3M Innovative Properties Co Alum-containing coating formulations for microneedle vaccine patches
GB2556002B (en) * 2015-07-07 2020-12-16 Bluewillow Biologics Inc Methods and compositions for nanoemulsion vaccine formulations
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
EP4395818A4 (en) * 2021-09-02 2025-08-20 Vaxcyte Inc STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2178A1 (fr) * 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
WO2000037105A2 (en) * 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
KR101916787B1 (ko) * 2005-03-23 2019-01-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Cd4 t-세포 및/또는 개선된 b-메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP2010501012A (ja) * 2006-08-17 2010-01-14 ザ ユーエービー リサーチ ファウンデーション 免疫原性PcpAポリペプチドおよびその使用
WO2009012588A1 (en) 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
AU2009208299B2 (en) * 2008-02-01 2015-01-22 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
CA2748149C (en) * 2008-12-24 2018-03-06 Netherlands Vaccine Institute Modified steptococcus pneumonia pneumolysin (ply) polypeptides

Similar Documents

Publication Publication Date Title
JP2013515015A5 (cg-RX-API-DMAC7.html)
US12083173B2 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
US11084850B2 (en) Recombinant prefusion RSV F proteins and uses thereof
CN102802664B (zh) 免疫原性组合物
JP2011514337A5 (cg-RX-API-DMAC7.html)
JP2010539172A5 (cg-RX-API-DMAC7.html)
CA2680193C (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
WO2014018904A1 (en) Fused antigen vaccines and compositions against streptococcus pneumoniae
CN104023744A (zh) 用于针对金黄色葡萄球菌免疫的稳定组合物
RU2014151424A (ru) Термостабильные составы вакцины
KR20110091560A (ko) 글루타밀 tRNA 합성효소(GtS) 단편들
JP2017505624A (ja) 新規治療法
EP2804627B1 (en) Fused antigen vaccines and compositions against streptococcus pneumoniae
IS7671A (is) Ónæmisvaka samsetningar
WO2015049633A1 (es) FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO.
Lu et al. Systemic and mucosal immune responses elicited by intranasal immunization with a pneumococcal bacterium-like particle-based vaccine displaying pneumolysin mutant Plym2
US20220152182A1 (en) Vaccine
US20140314812A1 (en) Live, attenuated streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease
EP3116537A2 (en) Immunogenic compositions